Foresee Pharmaceuticals Co., Ltd. (TPEX: 6576)

Foresee Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	972.76	1,010	689.51	871.44	1,145	448.02
Short-Term Investments	-	150	-	100	125	-
Trading Asset Securities	-	-	-	297.47	351.68	48.16
Cash & Short-Term Investments	972.76	1,160	689.51	1,269	1,622	496.17
Cash Growth	-42.77%	68.19%	-45.66%	-21.76%	226.86%	131.50%
Accounts Receivable	53.28	65.91	16.27	-	-	-
Other Receivables	25.17	22.18	10.13	5.73	13.97	13.72
Receivables	78.45	88.09	26.4	5.73	13.97	13.72
Inventory	130.37	126.8	176.41	24.88	34.11	39.72
Prepaid Expenses	54.27	23.56	22.75	3.9	9.71	2.64
Other Current Assets	100	192.5	-	-	6.62	-
Total Current Assets	1,336	1,591	915.06	1,303	1,686	552.25
Property, Plant & Equipment	128.99	135.01	142.39	91.19	110.8	117.36
Other Intangible Assets	119.75	126.81	140.96	155.14	209.44	243.95
Long-Term Deferred Tax Assets	1.29	1.23	1.22	1.1	1.14	1.2
Other Long-Term Assets	7.52	7.76	104.39	90.58	92.06	94.49
Total Assets	1,593	1,861	1,304	1,641	2,100	1,009
Accounts Payable	41.52	12.13	22.85	-	-	-
Accrued Expenses	79.6	120.71	78.47	61.68	45.8	41.01
Short-Term Debt	200	200	-	-	30.07	-
Current Portion of Long-Term Debt	-	-	-	-	20.79	-
Current Portion of Leases	13.99	15.14	15.52	10.2	9.38	10.06
Current Income Taxes Payable	9.35	10.42	4.95	-	-	-
Current Unearned Revenue	151.58	105.48	1.01	0.78	1.52	9.32
Other Current Liabilities	4.38	6.96	6.38	1.79	14.03	3.09
Total Current Liabilities	500.43	470.83	129.17	74.45	121.59	63.48
Long-Term Debt	-	-	-	-	63.24	-
Long-Term Leases	5.73	13.12	25.8	6.45	6.68	2.53
Long-Term Unearned Revenue	85.56	131.67	237.15	239.17	77.67	46.1
Long-Term Deferred Tax Liabilities	1.39	1.32	1.32	1.19	1.22	1.29
Total Liabilities	593.11	616.93	393.43	321.26	270.4	113.4
Common Stock	1,360	1,358	1,182	1,179	1,169	1,003
Additional Paid-In Capital	4,646	4,617	3,424	3,372	3,319	2,038
Retained Earnings	-5,013	-4,730	-3,693	-3,221	-2,651	-2,141
Comprehensive Income & Other	8.68	-1.49	-1.54	-10.21	-8.06	-4.58
Shareholders' Equity	1,000	1,245	910.58	1,320	1,829	895.86
Total Liabilities & Equity	1,593	1,861	1,304	1,641	2,100	1,009
Total Debt	219.72	228.26	41.32	16.65	130.15	12.59
Net Cash (Debt)	753.04	931.42	648.19	1,252	1,492	483.59
Net Cash Growth	-51.90%	43.70%	-48.24%	-16.05%	208.45%	125.63%
Net Cash Per Share	5.54	7.32	5.49	10.67	14.71	5.04
Filing Date Shares Outstanding	135.96	135.82	118.17	117.94	116.94	100.33
Total Common Shares Outstanding	135.96	135.82	118.17	117.94	116.94	100.33
Working Capital	835.42	1,120	785.89	1,229	1,565	488.77
Book Value Per Share	7.36	9.16	7.71	11.19	15.64	8.93
Tangible Book Value	880.53	1,118	769.62	1,165	1,620	651.9
Tangible Book Value Per Share	6.48	8.23	6.51	9.88	13.85	6.50
Machinery	225.5	209.45	171.58	136.94	144.58	57.45
Construction In Progress	13.25	4.9	20.39	4.4	1.31	77.95
Leasehold Improvements	30.44	30.44	7.71	7.71	7.71	9.51

Source: S&P Capital IQ. Standard template. Financial Sources.